Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01836068 · ClinicalTrials.gov registry record · Early Phase 1
Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals
A Early Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 11
- Enrollment target
NCT01836068 is a Early Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 11 participants.
The verdict
NCT01836068, a Early Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
To find out if it is possible for HIV-1 patients to maintain antiretroviral medications during allogeneic bone marrow transplant
Interventions
- DRUG Enfuvirtide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2013-06 |
| Est. Completion | 2021-06-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01836068
The ClinicalTrials.gov registry entry for NCT01836068 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enfuvirtide is the first listed.
NCT01836068 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01836068 about?
NCT01836068 is a clinical study titled "Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals". To find out if it is possible for HIV-1 patients to maintain antiretroviral medications during allogeneic bone marrow transplant
What is the current status of trial NCT01836068?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 11 participants. The study started on 2013-06. Estimated completion is 2021-06-05.
What interventions are being tested in trial NCT01836068?
The interventions under investigation include: Enfuvirtide (DRUG).
Who is sponsoring clinical trial NCT01836068?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.